ArticleJournal of orthopaedic case reports2026
Effect of Routes of Administration of Tranexamic Acid in Peri-Operative Blood Loss in Total Hip Arthroplasty: A Prospective Comparative Study.
Article in Journal of orthopaedic case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Perioperative blood loss is a significant challenge in total hip arthroplasty (THA), and it often necessitates blood transfusion. Tranexamic acid (TXA), an antifibrinolytic agent, is widely used to reduce surgical blood loss, but to date; there is no clear consensus on the optimal and most efficacious route of administration of TXA. Therefore, this study was planned to evaluate and compare the efficacy of different routes of administration of TXA in reducing perioperative blood loss through a prospective comparative study. Materials and Methods: A total of 102 patients undergoing elective unilateral THA were enrolled and randomized into three cases and their three control groups of 17 patients each. The patients in group A (intravenous [IV]-TXA group) received IV-TXA while its control Group D received an equivalent amount of IV normal saline (NS). Group B (Topical-TXA group), received topical TXA, while its control Group E received an equivalent amount of NS at similar stages in a similar fashion. Group C (combined-TXA group) received IV as well as topical TXA, while its control Group F received an equivalent amount of NS at similar stages. Perioperative blood loss was measured from suction cylinders, mop weight and drain output. Statistical analysis included analysis of variance, post hoc Tukey tests, and independent t-tests. Results: All TXA groups showed reduced blood loss as compared to their controls. Among these, the combined-TXA group demonstrated the lowest total mean blood loss (629.29 ± 26.33 mL), followed by the IV-TXA and topical-TXA group. These differences were statistically significant (P < 0.05). No adverse events were reported in the case or control groups. Conclusion: The route of TXA administration plays a significant role in its efficacy in reducing perioperative blood loss. The combined (IV+ Topical) route is more effective in reducing intraoperative and post-operative blood loss as compared to IV or topical routes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.